No internet connection — showing the saved version of the page.

Opko Health Inc

USUSD
← to the screener

Opko Health Inc (LSE:0KCS) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
opko.com
Investor relations
opko.com/investors
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
Miami, United States
Management
Phillip Frost
Latest reports
quarterly 2026 · 10-Q for the period ended 2026-03-31
Employees
2 275
Founded
1991
Shares outstanding
746.33 M as of 2026-07-17
Free float
323.73 M
Market cap
1.17 B USD
Insiders
50.52%
Institutions
27.56%
Industry (SIC)
Pharmaceutical Preparations
Legal form
Corporation
ISIN
US68375N1037
LEI
529900A4S2D4OGOJLL02
P/E
loss
P/B
2.05
FCF
−134 M USD
Debt
349 M USD
negative FCF — not covered
Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
NAV
0.79 USD · P/NAV 2.07
Balance sheet date30.06.2026
Assets1.83 B USD
− Liabilities645 M USD
= NAV (equity of the company's shareholders)1.18 B USD
− Goodwill482 M USD
− Intangible assets478 M USD
= Tangible NAV225 M USD
Shares1 492 656 450
NAV per share0.79 USD
Tangible NAV per share0.15 USD
Share price (0KCS)1.6400 USD
P/NAV2.07
NAV history
Balance sheet dateNAVNAV per share
30.06.20261.18 B USD0.79 USD
31.03.20261.20 B USD0.80 USD
31.12.20251.27 B USD1.67 USD
30.09.20251.31 B USD1.70 USD
30.06.20251.30 B USD1.63 USD
31.03.20251.31 B USD1.65 USD
31.12.20241.37 B USD1.02 USD
30.09.20241.40 B USD2.06 USD
Description

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksOPK primaryUSD1.63 +0.00%common stock
LSE London Stock Exchange0KCS IOBUSD1.64 +0.00%common stock
TA Tel Aviv Stock ExchangeOPK secondaryILS—

Price for 3 months

up day down dayHover / tap a day — open, close, high and low prices

News this week

Press releases from the company's investor website, updated daily. Links lead to the company's website. Headlines are in the original language, as on the company website.

Top holders

HolderStakeSharesReport date
Rubric Capital Managemen…6.4%47.79 M2026-06-30
Blackrock Inc.4.95%36.98 M2026-06-30
Vanguard Capital Managem…2.01%14.97 M2026-06-30
Vanguard Portfolio Manag…2%14.93 M2026-06-30
Geode Capital Management…1.55%11.58 M2026-06-30
iShares Trust-iShares Ru…1.38%10.32 M2026-08-31
State Street Corporation1.38%10.31 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.31%9.75 M2026-06-30
Goldman Sachs Group Inc0.94%7.04 M2026-06-30
VANGUARD INDEX FUNDS-Van…0.93%6.92 M2026-06-30
UBS Group AG0.67%5.01 M2026-06-30
VANGUARD INDEX FUNDS-Van…0.66%4.91 M2026-06-30
Whitefort Capital Manage…0.6%4.51 M2026-06-30
Fidelity Salem Street Tr…0.58%4.35 M2026-07-31
iShares Trust-iShares Ru…0.51%3.79 M2026-08-31
Northern Trust Corporati…0.5%3.76 M2026-06-30
iShares Trust-iShares Bi…0.38%2.81 M2026-08-31
VANGUARD INDEX FUNDS-Van…0.29%2.2 M2026-06-30
VANGUARD SCOTTSDALE FUND…0.28%2.11 M2026-05-31
SCHWAB STRATEGIC TRUST-S…0.27%2.04 M2026-05-31
PAGANELLI JOHN A (Direct…≈0.05%403 5152026-03-20
FROST PHILLIP MD ET AL (…——2025-11-21